Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Cardiovascular disease(CVD) is the leading cause of morbidity and mortality in developed
nations. CVD is primarily caused by atherosclerosis, a systemic disease characterized by
lipid deposition in the subendothelial space with a concomitant, low-grade inflammatory
reaction.(Fuster, Moreno et al. 2005) To date, most therapeutic interventions aimed at
lowering CVD have thus far focused on modulating lipid levels, either lowering LDLc or
increasing HDLc levels. Yet, since the introduction of statins 20 years ago, there have been
few breakthroughs in the treatment of this disease. A promising strategy to reduce CVD is to
directly target inflammation at the level of the vessel wall.(van Leuven, van Wijk et al.;
Libby 2002) A potential drawback of anti-inflammatory strategies pertains to the thin line
between inhibiting 'inappropriate' inflammation versus inducing immuno-suppression.
Therefore, continuous low dosed anti-inflammatory drugs have great potential as novel
treatment strategies. In the present project, the investigators propose to inject liposomal
glucocorticoids intravenously in patients with an increased risk of atherosclerotic disease
aiming to reduce vessel wall inflammation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)